Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Jockey receives two-year suspension
endurance riding
Endurance riding is based on controlled long-distance races. (stock photo)

FEI publishes decision on prohibited substance case

The FEI tribunal has published its final decision regarding samples taken from the horse Lunatica in Doha on 2 May 2015. The rider, Abdulla Mahmood Abdulla Darban rode the horse into fourth position in the CEI1 endurance event.

The horse returned positive samples for Propranolol and Dexamethasone, both prohibited under the FEI’s Equine Anti-Doping and Controlled Medication Rules (EADCMRs).

The Qatar based athlete also received a fine of CHF 2,000 and was ordered to contribute to the cost of the judicial proceedings. His ban will take immediate effect and run until 22 June 2017.

Propranolol, which is a beta-blocker used to lower the heart rate, is on the FEI’s banned substance list, and should therefore never be found in a competing horse’s system.  

As a controlled medication, the corticosteroid Dexamethasone is on the controlled medication list, and should have been cleared from the horse’s system by the time of competing.

The report states that the athlete acted in violation of the FEI’s Equine Anti-Doping rules and that the rider has “failed in his duty of utmost caution to ensure that the Horse has not ingested any Prohibited Substance.”

The rider must take any appeal to the Court of Arbitration for Sport in the next 30 days.

Image © olgaru79

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'